Prognostic incremental role of right ventricular function in acute decompensation of advanced chronic heart failure.

AIMS: The purpose of this study was to evaluate the additional prognostic value of echocardiography in acute decompensation of advanced chronic heart failure (CHF), focusing on right ventricular (RV) dysfunction and its interaction with loading conditions. Few data are available on the prognostic role of echocardiography in acute HF and on the significance of pulmonary hypertension in patients with severe RV failure. METHODS AND RESULTS: A total of 265 NYHA IV patients admitted for acute decompensation of advanced CHF (EF 22 ± 7%, systolic blood pressure 107 ± 20 mmHg) were prospectively enrolled. Fifty-nine patients met the primary composite endpoint of cardiac death, urgent heart transplantation, and urgent mechanical circulatory support implantation at 90 days. Pulmonary hypertension failed to predict events, while patients with a low transtricuspid systolic gradient (TR gradient <20 mmHg) showed a worse outcome [hazard ratio (HR) 2.37, 95% confidence interval (CI) 1.12-5.00, P = 0.02]. RV dysfunction [tricuspid annular plane systolic excursion (TAPSE) ≤14 mm] in the presence of a low TR gradient identified patients at higher risk of events (HR 2.97, 95% CI 1.19-7.41, P = 0.02). Multivariate analysis showed as best predictors of outcome low RV contraction pressure index (RVCPI), defined as TAPSE × TR gradient, and high estimated right atrial pressure (eRAP). Adding RVCPI (<400 mm*mmHg) and eRAP (≥20 mmHg) to conventional clinical (ADHERE risk tree and NT-proBNP) and echocardiographic risk evaluation resulted in an increase in net reclassification improvement of +19.1% and +20.1%, respectively (P = 0.01) and in c-statistic from 0.59 to 0.73 (P < 0.01). CONCLUSIONS: In acute decompensation of advanced CHF, pulmonary hypertension failed to predict events. The in-hospital and short-term prognosis can be better predicted by eRAP and RVCPI.

Echocardiography-guided versus fluoroscopy-guided temporary pacing in the emergency setting: an observational study.

BACKGROUND: The insertion of a temporary pacemaker can be a lifesaving procedure in the emergency setting. OBJECTIVES: This is an observational monocentric study comparing echocardiography-guided temporary pacemaker via the right internal jugular vein to standard fluoroscopy-guided temporary pacemaker via the femoral vein; the procedure was tested for noninferiority. METHODS: Patients needing urgent pacing were consecutively enrolled. Primary efficacy endpoints were time to pacing and need for catheter replacement. Primary safety endpoint was a composite outcome of overall complications. RESULTS: One hundred and six patients (77 ± 10 years) were enrolled: 53 underwent echocardiographic-guided and 53 fluoroscopy-guided temporary pacemaker. Baseline characteristics of the two groups of treatment were similar. Time to pacing was shorter in the echocardiography-guided than in the fluoroscopy-guided group (439 ± 179 vs. 716 ± 235 s; P<0.0001; power 100%). During the pacing (54 ± 35 h), there was a higher incidence of pacemaker malfunction in the fluoroscopy-guided group [15 vs. 3 patients; odds ratio (OR) 6.5, confidence interval (CI) 95% 1.9-29.7, P<0.001; power 5.7%] and there was a significantly lower incidence of complications in the echocardiography-guided temporary pacemaker group (6 vs. 22 patients; OR 0.18, CI 95% 0.06-0.49, P<0.001; echocardiography-guided temporary pacemaker events rate 0.1929 vs. fluoroscopy-guided temporary pacemaker events rate 1.398 per 100 person-hours paced, P<0.0001). In the standard group there was one death attributable to a temporary pacemaker complication (sepsis). CONCLUSION: Echocardiography-guided temporary pacemaker is a well-tolerated procedure that could allow reliable insertion of a temporary pacemaker; therefore, it is a well-tolerated option in an emergency setting and in hospitals where fluoroscopy is not available.

Fatal pulmonary embolism: when the cause is not a thrombus.

STUDY DESIGN: We report a case of pulmonary embolism of polymethylmethacrylate material after percutaneous vertebroplasty. OBJECTIVE: To describe a severe vertebroplasty complication, the pulmonary embolism, which proved to be fatal in a patient with many chronic disabilities. SUMMARY OF BACKGROUND DATA: Until 2007, the literature noted that the risk of embolism of polymethylmethacrylate after a percutaneous vertebroplasty counted a small number of pulmonary cement embolism and a smaller number of fatal consequences. The most recent research revealed that the risk of a pulmonary cement embolism ranges from 3.5% to 23% for osteoporotic compression fractures. METHODS: This study is a case report of an 80-year-old patient with multiple medical comorbid factors, chronic obstructive pulmonary disease, mild renal failure, osteoporosis, and hepatic cirrhosis. Symptoms of pulmonary embolism developed 1 month after a percutaneous vertebroplasty. An echocardiography report suggested that the cement infiltrated the right atrium and the right pulmonary artery, and this was confirmed by a computed tomographic scan. As the therapy with oxygen and low-molecular-weight heparin failed to solve the thrombus, the patient required a surgical tricuspid annuloplasty and the extirpation of the right atrial and right pulmonary masses. RESULTS: The course of the operation was complicated by pulmonary infection, and the patient ultimately succumbed to infection/respiratory failure. CONCLUSION: The presence of intravascular/intracardiac foreign bodies is underreported in literature, but it is quite common in clinical practice. We need to discuss the choice of some non-risk-free interventions such as vertebroplasty in older patients already affected by multiple main disabilities.

Refractory acute decompensated heart failure: an observational study on a noninvasive hemodynamic monitoring system aimed at improving the therapeutic approach.

BACKGROUND: Inotropic agents should only be administered in acute decompensated heart failure (ADHF) refractory to vasodilators at optimal doses because they are associated with adverse outcome. In this setting a noninvasive hemodynamic monitoring system (NHMS) could be useful for optimizing treatment. INCLUSION CRITERIA: advanced chronic heart failure, ejection fraction 30% or less, admission for ADHF with systolic blood pressure 115 mmHg or less and inadequate response at 48 h of therapy. Patients were evaluated with a NHMS: with vascular systemic resistance (VSR) greater than 1500 dyne x s/cm we used vasodilators at increasing doses, with VSR less than 1500 and cardiac index (CI) less than 2.4 l/min per m inotropic agents were used. RESULTS: The study population consisted of 20 patients (mean age 67 + or - 12 years) with ejection fraction 20 + or - 7%. After 48 h of clinical-guided therapy, none of the patients achieved VSR 1500 or less, and 12 patients had a CI less than 2.4 l/min per m. After hemodynamic-guided therapeutic optimization there was a significant reduction of dyspnea at rest (7.7 + or - 1.25 versus 2.44 + or - 1.33 on the 10-point Likert scale, P < 0.001) and 'cold' presentation (12 patients before and 1 patient after, P = 0.0004). Daily urinary volume was higher (1217 + or - 369 versus 2260 + or - 797 ml, P = 0.001) without renal function deterioration (creatinine 1.56 + or - 0.52 versus 1.34 + or - 0.61 mg/dl, P = 0.012).The nitroprusside dosing was increased after NHMS (0.13 + or - 0.19 versus 0.4 + or - 0.310 microg/kg per min, P = 0.044), whereas doses of inotropic agents, diuretics and beta-blockers did not change significantly. CONCLUSIONS: In refractory ADHF a NHMS improves significantly symptoms and renal function, with a better use of vasodilators.

[Temporary emergency cardiac pacing under continuous echocardiographic control. Feasibility and safety of the procedure without using fluoroscopy]. / Posizionamento ecoguidato di elettrostimolatore temporaneo endocavitario in emergenza. Fattibilità e sicurezza della procedura senza impiego di fluoroscopia.

BACKGROUND: Cardiac pacing often turns out to be the only effective treatment of severe brady-arrhythmias. Several invasive and noninvasive temporary pacing procedures are known, whose application is sometimes difficult or time-consuming. An alternative temporary cardiac pacing procedure is described in this article, which is based on echocardiographic control. METHODS: Fifty-four nonconsecutive patients were studied; they all were needing urgent cardiac pacing. A first choice attempt to perform an ultrasound-guided temporary cardiac pacing, by using a right jugular venous approach, was done. The catheter pathway was monitored by means of echocardiography performed by another operator. All data concerning time of execution, pacing parameters, acute or chronic complications and the in situ time duration of the catheter without needing to be repositioned were obtained. RESULTS: Ultrasound-guided cardiac pacing was not feasible in 3 patients (6%), because of a high thoracic acoustic impedance or failing to perform right jugular venous catheterization. Mean execution time was 680 +/- 179 s. Echocardiographic monitoring was performed in 50 patients by a cardiologist, in 1 patient by a non-cardiologist physician, and in 3 patients by a nurse, who had been previously trained to keep the transducer in the right position. No serious complications occurred. On 4 occasions (8%) the catheter had to be repositioned during the following hours. On 25 occasions (46%) permanent cardiac pacing was finally performed. CONCLUSIONS: Temporary ultrasound-guided cardiac pacing seems to be a safe and easy procedure; it can be performed in a broad range of clinical and logistic scenarios and does not require fluoroscopic monitoring. A limited number of human resources is needed, but technical skills in central venous catheterization are required. Further studies are needed to validate this procedure; however it shows several potential benefits as compared to the other temporary cardiac pacing techniques.

[Bolus injection of recombinant tissue-type plasminogen activator during cardiopulmonary resuscitation in massive pulmonary embolism complicated with heart arrest. Report of 2 cases and review of the literature]. / Somministrazione di attivatore tissutale del plasminogeno ricombinante in bolo durante rianimazione cardiopolmonare nell'embolia polmonare massiva complicata da arresto cardiaco. Descrizione di due casi e revisione della letteratura.

In the early phase of fulminant pulmonary embolism mortality is extremely high, with 50% of all deaths occurring within 2 hours after the onset of symptoms. We describe 2 cases of massive pulmonary embolism accompanied by cardiac arrest requiring cardiopulmonary resuscitation. The patients received 100 mg of recombinant tissue-type plasminogen activator in bolus injection and showed a definite improvement in the clinical-hemodynamic status. In our opinion, bolus lysis made a definitive contribution to the success of resuscitation. Several other case reports and small series showed successful treatment of pulmonary embolism during similar circumstances using high-dose bolus injection of thrombolytic agents. We conclude that bolus administration of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism may be an acceptable and successful technique, available also in community hospitals.